Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

Abstract Background The role of adjuvant radiation in pancreatic adenocarcinoma (PDAC) remains unclear. We aimed to investigate the efficacy of gemcitabine combined with stereotactic body radiation therapy (SBRT) as adjuvant therapy for resected stage II PDAC. Methods In this single-center randomize...

Full description

Bibliographic Details
Main Authors: Tao Ma, Xueli Bai, Qichun Wei, Yongjie Shui, Mengyi Lao, Wen Chen, Bingfeng Huang, Risheng Que, Shunliang Gao, Yun Zhang, Wei Chen, Ji Wang, Tingbo Liang
Format: Article
Language:English
Published: BMC 2022-08-01
Series:BMC Cancer
Subjects:
Pancreatic adenocarcinoma
Adjuvant therapy
Gemcitabine
SBRT
Randomized controlled trial
Online Access:https://doi.org/10.1186/s12885-022-09974-7

Internet

https://doi.org/10.1186/s12885-022-09974-7

Similar Items